Indian Immunologicals Limited, a active public limited company, was established on 08 October 1999 in Hyderabad, Telangana, India. Engaging in animal pharmaceuticals & healthcare within the manufacturing sector, it holds CIN: U72200TG1999PLC032666. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹400.00 Cr and a paid-up capital of ₹54.00 Cr.
It upholds a compliant status. Its leadership includes Meeneshkumar Champaklal Shah (Director), Rajeev Sivarama (Director), Anand Kumar Kanakasapapathy (Managing Director). Past directors included Balasubramaniam Venkatasubramaniam Kollengode, Deepak Tikku, Villuppanoor Alwar Srinivasan. It holds ₹335.16 Cr open charges and ₹887.42 Cr settled loans. Its latest AGM occurred on 12 September 2025, with the balance sheet filed on 31 March 2025. It is based at Indian Immunologicals Limited, Road No. 44, Jubilee Hills, Hyderabad, Telangana, 500033.
U72200TG1999PLC032666
032666
08 October 1999
₹400.00 Cr
₹54.00 Cr
Roc Hyderabad
Unlisted
Active
Explore comprehensive insights into Indian Immunologicals Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Meeneshkumar Champaklal Shah | Director | 15 Jul 2021 | Current |
| Rajeev Sivarama | Director | 06 Aug 2021 | Current |
| Anand Kumar Kanakasapapathy | Managing Director | 01 Nov 2013 | Current |
| Usha Ramachandra | Director | 18 Mar 2025 | Current |
| Devanand Chakkingal Pathayapura | Director | 12 Nov 2021 | Current |
| Venkateswara Rao Thallapaka | Director | 18 Mar 2025 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Managing Director | 31 Mar 2016 | Past |
| Pramod Abcsdd | Director | 25 Sep 2014 | Past |
| Pramod Abcsdd | Director | 30 Jul 2021 | Past |
| Pramod Abcsdd | Director | 15 Apr 2014 | Past |
| Pramod Abcsdd | Director | 09 Oct 2014 | Past |
| Pramod Abcsdd | Additional Director | 20 Sep 2021 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Indian Immunologicals Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 9.74% increase. The company also saw a substantial improvement in profitability, with a 239.81% increase in profit. The company's net worth Soared by an impressive increase of 25.26%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Indian Immunologicals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹3,351,600,000.00
₹8,874,185,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 05 May 2016 | Others | ₹5.00 Cr | Open |
| 18 Mar 2016 | Others | ₹85.16 Cr | Open |
| 12 Dec 2013 | Others | ₹40.00 Cr | Open |
| 14 Dec 2011 | Others | ₹85.00 Cr | Open |
| 02 Sep 2010 | Hdfc Bank Limited | ₹120.00 Cr | Open |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with Indian Immunologicals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Indian Immunologicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Indian Immunologicals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Indian Immunologicals Limited last Annual general meeting of members was held on 12 Sep 2025 as per latest MCA records. was completed.
The activity Indian Immunologicals Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad. was completed.
Usha Ramachandra was appointed as a Director was appointed as a Director on 18 Mar 2025 & has been associated with this company since 8 months 8 days . was recorded as a recent event.
Progress on Venkateswara Rao Thallapaka was appointed as a Director was appointed as a Director on 18 Mar 2025 & has been associated with this company since 8 months 8 days . was documented.
A charge with Others of Rs. 5.00 Cr registered on 05 May 2016 with Charge ID 100031486 was modified on 05 Mar 2025. was recorded as a recent event.
A charge with Others of Rs. 85.00 Cr registered on 14 Dec 2011 with Charge ID 10327282 was modified on 05 Mar 2025. was recorded as a recent event.
The brand-new unit will have a BSL3 facility for the manufacture of drug substances and a fill-finish capability for the production of both drug products FMD vaccine and the FMD+HS vaccine..
The CIN of Indian Immunologicals Limited is U72200TG1999PLC032666.
Indian Immunologicals Limited is headquartered at Indian Immunologicals Limited, Road No. 44, Jubilee Hills, Hyderabad, Telangana, 500033.
Indian Immunologicals Limited was incorporated on 08 October 1999.
The current directors of Indian Immunologicals Limited are
The primary industry of Indian Immunologicals Limited is Manufacturing.
Indian Immunologicals Limited is unlisted.
The authorized capital of Indian Immunologicals Limited is ₹400.00 Cr, and the paid-up capital is ₹54.00 Cr.
The compliance status of Indian Immunologicals Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX